PerkinElmer Acquires Spectral Genomics, Inc.
Molecular Karyotyping Technology Expected to Drive Advances in Prenatal and Neonatal Research and Disease Detection
Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders. The company's proprietary Array CGH (Comparative Genome Hybridization) technology provides a high-resolution global view of the human genome, enabling researchers to identify the exact location of any chromosomal deletions and amplifications that can cause an increased risk of genetic disease.
According to PerkinElmer, array-based karyotyping is widely expected to replace Florescent In-Situ Hybridization (FISH), G-banding microscopic analysis and other conventional forms of karyotyping in the cytogenetic market.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.